Immunogenicity of SARS-CoV-2 mRNA Vaccine in Breast Cancer Patients Undergoing Active Treatment: A Prospective Observational Study
Pathogens · 2025
DOI: 10.3390/pathogens14090947 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Pathogens, 2025. Verfasst von María Leonor Fernández-Murga und 8 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Oncology Laboratory, Arnau de Vilanova Hospital, Foundation for the Promotion of Health and Biomedical Research of the Valencian Community …. Hauptthemen laut MEDLINE: Breast Neoplasms, COVID-19, SARS-CoV-2, COVID-19 Vaccines. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Consellería de Sanitat Universal i Salut Pública (Generalitat Valenciana, Spain and the EU Operational Program of the European Regional Development Fund (ERDF)…, Consellería de Sanitat Universal i Salut Pública (Generalitat Valenciana, Spain), EU Operational Program of the European Regional Development Fund (ERDF) for the Valencian Community 2014–2020.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Understanding the immune response to SARS-CoV-2 vaccination in cancer patients remains a critical priority given their immunocompromised status. In this prospective observational study, we evaluated humoral and cellular immunity across three time points—baseline, post-second dose, and post-booster—in 23 breast cancer patients undergoing active treatment. IgG antibody levels showed a significant increase following vaccination, with a 300-fold rise after the second dose and a 2200-fold increase post-booster, indicating a strong humoral response. CD19+ B cells also increased significantly, supporting B cell-mediated activation. Although overall T cell frequencies remained stable, we observed a shift toward memory phenotypes, with decreased naïve CD4+ and CD8+ T cells and increased central and peripheral memory subsets after the booster. Notably, CD8+ TEMRA cells expanded significantly, suggesting cytotoxic memory formation. Correlation analyses linked peripheral memory CD4+ T cells with anti-SARS-CoV-2 IgG titers, while CD8+ TEMRA cells showed an inverse association. Antigen-specific CD8+ T cell response was evaluated using APC-labeled MHC I Dextramer reagents. After the booster, 55.5% of patients developed detectable antigen-specific CD8+ T cells, whereas 44.5% did not. Importantly, one patient who failed to develop antigen-specific CD8+ T cells experienced a mild SARS-CoV-2 infection, suggesting that the absence of this response may increase susceptibility despite high IgG levels. These findings indicate that antigen-specific CD8+ T cell responses and antibody levels may act as complementary but not directly correlated arms of immunity. Microbiota profiling via sPLS-DA suggested weak but distinct microbial signatures associated with immune responsiveness, particularly enrichment of taxa such as Alistipes and Romoutsia among high-antibody responders. These findings emphasize that SARS-CoV-2 vaccination is immunogenic and well tolerated in breast cancer patients under therapy and highlight the need to further explore microbiota–immune interactions to optimize vaccination strategies in oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Oncology Laboratory, Arnau de Vilanova Hospital, Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO), 46015 Valencia, Spain.
- Sequencing and Bioinformatics Service, Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO), Avda. de Catalunya 21, 46020 Valencia, Spain.
- Microbiology Department, Arnau de Vilanova Hospital, Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO), 46015 Valencia, Spain.
ORCID-Profile: María Leonor Fernández-Murga, Lucía Serrano-García, Giuseppe D'Auria, Llúcia Martínez-Priego, Antonio Llombart-Cussac
Förderung
- Consellería de Sanitat Universal i Salut Pública (Generalitat Valenciana, Spain and the EU Operational Program of the European Regional Development Fund (ERDF)…
- Consellería de Sanitat Universal i Salut Pública (Generalitat Valenciana, Spain)
- EU Operational Program of the European Regional Development Fund (ERDF) for the Valencian Community 2014–2020
Zitieren
APA
Fernández-Murga, M. L., Serrano-García, L., D'Auria, G., Hernández, M. P., Martínez-Priego, L., Ferrús-Abad, L., de Marco, G., Domínguez-Márquez, M. V., & Llombart-Cussac, A. (2025). Immunogenicity of SARS-CoV-2 mRNA Vaccine in Breast Cancer Patients Undergoing Active Treatment: A Prospective Observational Study. Pathogens. https://doi.org/10.3390/pathogens14090947
Vancouver
Fernández-Murga ML, Serrano-García L, D'Auria G, Hernández MP, Martínez-Priego L, Ferrús-Abad L, et al. Immunogenicity of SARS-CoV-2 mRNA Vaccine in Breast Cancer Patients Undergoing Active Treatment: A Prospective Observational Study. Pathogens. 2025. doi:10.3390/pathogens14090947
BibTeX
@article{FernndezMurga2025,
author = {Fernández-Murga, María Leonor and Serrano-García, Lucía and D'Auria, Giuseppe and Hernández, María Portero and Martínez-Priego, Llúcia and Ferrús-Abad, Loreto and de Marco, Griselda and Domínguez-Márquez, María Victoria and Llombart-Cussac, Antonio},
title = {Immunogenicity of SARS-CoV-2 mRNA Vaccine in Breast Cancer Patients Undergoing Active Treatment: A Prospective Observational Study},
journal = {Pathogens},
year = {2025},
doi = {10.3390/pathogens14090947}
}
EUVIMED